Literature DB >> 19540573

Primary atherothrombotic occlusive vascular events in premenopausal women with history of adverse pregnancy outcome.

S Ben-Ami1, G Oron, A Ben-Haroush, D Blickstein, M Hod, J Bar.   

Abstract

OBJECTIVE: To determine if adverse pregnancy outcomes are associated with atherothrombotic occlusive vascular disease (AOVD) in premenopausal women.
DESIGN: Retrospective matched case-control study.
SETTING: Tertiary, university-affiliated medical center. POPULATION: Women aged less than 50 years treated for an AOVD (primary cerebrovascular, myocardial, or peripheral arterial ischemic event) from 1995 to 2004.
METHOD: The files were reviewed for classical risk factors for AOVD and complications of pregnancy (abortions, pregnancy-induced hypertension, preeclampsia, gestational diabetes, intrauterine growth restriction (IUGR), fetal loss and preterm delivery). Findings were compared with healthy women matched for age and body mass index. MAIN OUTCOME MEASURES: Past pregnancy complications in premenopausal women with AOVD.
RESULTS: Of the 101 women with AOVD, 53 had a myocardial ischemic event, 33 a cerebrovascular event, and 15 a peripheral ischemic arterial event. On multivariate analysis, IUGR (OR 8.41, 95% CI 2.36-29.9, p=0.001) and more than one pregnancy complication (OR 13.7, 95% CI 1.56-120, p=0.02) were found to be independent significant variables associated with AOVD.
CONCLUSION: IUGR and composite pregnancy complications are independent significant variables associated with AOVD in premenopausal period. Pregnancy outcome might serve as a means to identify patients who may require increased medical surveillance and preventive measures for later vascular disease. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19540573     DOI: 10.1016/j.thromres.2009.05.017

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

Review 1.  Sex Differences in Peripheral Artery Disease.

Authors:  Maria Pabon; Susan Cheng; S Elissa Altin; Sanjum S Sethi; Michael D Nelson; Kerrie L Moreau; Naomi Hamburg; Connie N Hess
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 23.213

2.  Elevated lipoprotein(a) levels and homozygous human platelet antigen 1b (HPA-1b) genotype are risk factors for intrauterine growth restriction (IUGR).

Authors:  Andrea Gerhardt; Nadja Howe; Jan Steffen Krüssel; Ruediger Eberhard Scharf; Rainer Bernd Zotz
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

Review 3.  Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis.

Authors:  Morven Caroline Brown; Kate Elizabeth Best; Mark Stephen Pearce; Jason Waugh; Stephen Courtenay Robson; Ruth Bell
Journal:  Eur J Epidemiol       Date:  2013-02-09       Impact factor: 8.082

4.  Aspirin reduces long-term stroke risk in women with prior hypertensive disorders of pregnancy.

Authors:  Eliza C Miller; Amelia K Boehme; Nadia T Chung; Sophia S Wang; James V Lacey; Kamakshi Lakshminarayan; Charlie Zhong; Daniel Woo; Natalie A Bello; Ronald Wapner; Mitchell S V Elkind; Joshua Z Willey
Journal:  Neurology       Date:  2018-12-26       Impact factor: 11.800

5.  Association of sex and height with a lower ankle brachial index in the general population.

Authors:  Ridhima Kapoor; Colby Ayers; Alexis Visotcky; Peter Mason; Jacquelyn Kulinski
Journal:  Vasc Med       Date:  2018-06-04       Impact factor: 4.739

Review 6.  Hypertensive Disorders of Pregnancy and Future Cardiovascular Health.

Authors:  Karen Melchiorre; Basky Thilaganathan; Veronica Giorgione; Anna Ridder; Alessia Memmo; Asma Khalil
Journal:  Front Cardiovasc Med       Date:  2020-04-15

Review 7.  Cerebrovascular disease in women.

Authors:  Aditya Kumar; Louise McCullough
Journal:  Ther Adv Neurol Disord       Date:  2021-01-27       Impact factor: 6.570

Review 8.  Challenges associated with peripheral arterial disease in women.

Authors:  Jessica Barochiner; Lucas S Aparicio; Gabriel D Waisman
Journal:  Vasc Health Risk Manag       Date:  2014-03-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.